Skip to main content
. Author manuscript; available in PMC: 2015 Jan 28.
Published in final edited form as: AIDS. 2014 Jan 28;28(3):365–376. doi: 10.1097/QAD.0000000000000093

Table 2.

Incremental cost effectiveness ratios of HIV/HCV telaprevir-based treatment strategies

Undiscounted Discounted Incremental
Strategy % Attaining SVR Life Expectancy Cost ($) QALE Cost ($) QALY CER ($/QALY)
No treatment 0 13.240 198,700 6.760 --- --- ---
Dual therapy 30.8 13.761 221,900 7.600 23,200 0.839 27,700
PEG/RBV trial 72.1 14.459 264,200 8.728 42,300 1.128 37,500
IL28B triage 72.3 14.463 269,200 8.743 5,000 0.016 319,400
Triple therapy 72.5 14.462 277,700 8.750 8,500 0.007 1,240,000

QALY: quality-adjusted life year; CER: cost-effectiveness ratio; PEG/RBV: Peginterferon and Ribavirin; IL28B: interleukin-28B

Note: all costs and QALYs are lifetime and discounted at an annual rate of 3%. Costs are in 2011 US dollars and rounded to the nearest $100. All life-years and QALYs are rounded to the nearest thousandth.